Evidence map›Paper›PMID 22264274›Full record

ArticleBreast cancer research : BCR2012

STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.

Szeman Ruby Chan, William Vermi, Jingqin Luo, Laura Lucini, Charles Rickert, Amy M Fowler, Silvia Lonardi, Cora Arthur, Larry Jt Young, David E Levy and 3 more

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 195 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. RUNX1-deficiency drives immune-active ERbioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Precision preclinical modeling to advance cancer treatment.Journal of the National Cancer Institute · 2025
    Review
  17. Article
  18. Article
  19. Vaccines targetingHuman vaccines & immunotherapeutics · 2024
    Article
  20. Rat Models of Hormone Receptor-Positive Breast Cancer.Journal of mammary gland biology and neoplasia · 2024
    Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Szeman Ruby ChanDepartment of Pathology and Immunology, Washington University School of Medicine, 425 S, Euclid Avenue, St, Louis, MO 63110, USA.
William Vermi
Jingqin Luo
Laura Lucini
Charles Rickert
Amy M Fowler
Silvia Lonardi
Cora Arthur
Larry Jt Young
David E Levy
Michael J Welch
Robert D Cardiff
Robert D Schreiber
Washington University in St. Louis · USUniversity of Brescia · ITMallinckrodt (United States) · USUniversity of California, Davis · USNew York University · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
Mechanisms of breast cancer progressionU01CA105490 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHODOSH, LEWIS A · 2004 to 2013
$6.7M
THE ROLE OF THE INTERFERONS IN CANCER IMMUNOEDITINGR01CA043059 · NCI · WASHINGTON UNIVERSITY · PI SCHREIBER, ROBERT DAVID · 1986 to 2014
$3.8M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA043059NCI NIH HHS U01 CA105490
6 · The paper itself

Abstract

introductionAlthough breast cancers expressing estrogen receptor-α (ERα) and progesterone receptors (PR) are the most common form of mammary malignancy in humans, it has been difficult to develop a suitable mouse model showing similar steroid hormone responsiveness. STAT transcription factors play critical roles in mammary gland tumorigenesis, but the precise role of STAT1 remains unclear. Herein, we show that a subset of human breast cancers display reduced STAT1 expression and that mice lacking STAT1 surprisingly develop ERα+/PR+ mammary tumors.

methodsWe used a combination of approaches, including histological examination, gene targeted mice, gene expression analysis, tumor transplantaion, and immunophenotyping, to pursue this study.

resultsForty-five percent (37/83) of human ERα+ and 22% (17/78) of ERα- breast cancers display undetectable or low levels of STAT1 expression in neoplastic cells. In contrast, STAT1 expression is elevated in epithelial cells of normal breast tissues adjacent to the malignant lesions, suggesting that STAT1 is selectively downregulated in the tumor cells during tumor progression. Interestingly, the expression levels of STAT1 in the tumor-infiltrating stromal cells remain elevated, indicating that single-cell resolution analysis of STAT1 level in primary breast cancer biopsies is necessary for accurate assessment. Female mice lacking functional STAT1 spontaneously develop mammary adenocarcinomas that comprise > 90% ERα+/PR+ tumor cells, and depend on estrogen for tumor engraftment and progression. Phenotypic marker analyses demonstrate that STAT1-/- mammary tumors arise from luminal epithelial cells, but not myoepithelial cells. In addition, the molecular signature of the STAT1-/- mammary tumors overlaps closely to that of human luminal breast cancers. Finally, introduction of wildtype STAT1, but not a STAT1 mutant lacking the critical Tyr701 residue, into STAT1-/- mammary tumor cells results in apoptosis, demonstrating that the tumor suppressor function of STAT1 is cell-autonomous and requires its transcriptional activity.

conclusionsOur findings demonstrate that STAT1 suppresses mammary tumor formation and its expression is frequently lost during breast cancer progression. Spontaneous mammary tumors that develop in STAT1-/- mice closely recapitulate the progression, ovarian hormone responsiveness, and molecular characteristics of human luminal breast cancer, the most common subtype of human breast neoplasms, and thus represent a valuable platform for testing novel treatments and detection modalities.

Indexed as

AdenocarcinomaAnimalsBiomarkers, TumorBreast NeoplasmsCell Line, TumorCell Transformation, NeoplasticCluster AnalysisDNA-Binding ProteinsDown-RegulationEpithelial CellsErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansBiomarkers, TumorDNA-Binding ProteinsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaprogesterone receptor BRag2 protein, mouseReceptors, ProgesteroneSTAT1 protein, humanStat1 protein, mouseSTAT1 Transcription Factor

Identifiers

PMID22264274
PMCPMC3496133
OpenAlexW2163301096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.